232 related articles for article (PubMed ID: 22973955)
41. Targeted therapy for metastatic colorectal cancer: role of aflibercept.
Mitchell EP
Clin Colorectal Cancer; 2013 Jun; 12(2):73-85. PubMed ID: 23102896
[TBL] [Abstract][Full Text] [Related]
42. Epidermal growth factor receptor as a target for chemotherapy.
Vallbohmer D; Lenz HJ
Clin Colorectal Cancer; 2005 Apr; 5 Suppl 1():S19-27. PubMed ID: 15871762
[TBL] [Abstract][Full Text] [Related]
43. [Monoclonal antibodies therapies for colorectal cancer: cétuximab, panitumumab and bevacizumab].
Piront P; Van Daele D; Belaiche J; Polus M
Rev Med Liege; 2009; 64(5-6):274-8. PubMed ID: 19642458
[TBL] [Abstract][Full Text] [Related]
44. The long and winding road to useful predictive factors for anti-EGFR therapy in metastatic colorectal carcinoma: the KRAS/BRAF pathway.
Russo A; Rizzo S; Bronte G; Silvestris N; Colucci G; Gebbia N; Bazan V; Fulfaro F
Oncology; 2009; 77 Suppl 1():57-68. PubMed ID: 20130433
[TBL] [Abstract][Full Text] [Related]
45. Emerging drugs in refractory colorectal cancer.
Nobili S; Galletta A; Brugia M; Tassi R; Petreni P; Landini I; Mini E
Future Med Chem; 2015 Aug; 7(12):1491-501. PubMed ID: 26293581
[TBL] [Abstract][Full Text] [Related]
46. Pharmacokinetic and pharmacodynamic evaluation of aflibercept for the treatment of colorectal cancer.
Sanz-Garcia E; Saurí T; Tabernero J; Macarulla T
Expert Opin Drug Metab Toxicol; 2015 Jun; 11(6):995-1004. PubMed ID: 25988772
[TBL] [Abstract][Full Text] [Related]
47. First-Line Treatment of Metastatic Colorectal Cancer: Interpreting FIRE-3, PEAK, and CALGB/SWOG 80405.
Elez E; Argilés G; Tabernero J
Curr Treat Options Oncol; 2015 Nov; 16(11):52. PubMed ID: 26374340
[TBL] [Abstract][Full Text] [Related]
48. Molecular Targeted Drugs and Treatment of Colorectal Cancer: Recent Progress and Future Perspectives.
Geng F; Wang Z; Yin H; Yu J; Cao B
Cancer Biother Radiopharm; 2017 Jun; 32(5):149-160. PubMed ID: 28622036
[TBL] [Abstract][Full Text] [Related]
49. Netrin-1 as a potential target for metastatic cancer: focus on colorectal cancer.
Ko SY; Blatch GL; Dass CR
Cancer Metastasis Rev; 2014 Mar; 33(1):101-13. PubMed ID: 24338005
[TBL] [Abstract][Full Text] [Related]
50. EGFR- and VEGF(R)-targeted small molecules show synergistic activity in colorectal cancer models refractory to combinations of monoclonal antibodies.
Poindessous V; Ouaret D; El Ouadrani K; Battistella A; Mégalophonos VF; Kamsu-Kom N; Petitprez A; Escargueil AE; Boudou P; Dumont S; Cervera P; Fléjou JF; André T; Tournigand C; Chibaudel B; de Gramont A; Larsen AK
Clin Cancer Res; 2011 Oct; 17(20):6522-30. PubMed ID: 21880790
[TBL] [Abstract][Full Text] [Related]
51. [Impact of mutational status of KRAS in the care of patients with colorectal cancer metastasis].
Assenat E; Ychou M
Bull Cancer; 2009 Dec; 96 Suppl():S41-6. PubMed ID: 20034869
[TBL] [Abstract][Full Text] [Related]
52. Current progress in targeted therapy for colorectal cancer.
Ortega J; Vigil CE; Chodkiewicz C
Cancer Control; 2010 Jan; 17(1):7-15. PubMed ID: 20010514
[TBL] [Abstract][Full Text] [Related]
53. Targeted Treatment against Cancer Stem Cells in Colorectal Cancer.
Martínez-Pérez J; Torrado C; Domínguez-Cejudo MA; Valladares-Ayerbes M
Int J Mol Sci; 2024 Jun; 25(11):. PubMed ID: 38892410
[TBL] [Abstract][Full Text] [Related]
54. Current status of nanoscale drug delivery systems for colorectal cancer liver metastasis.
Hong Y; Rao Y
Biomed Pharmacother; 2019 Jun; 114():108764. PubMed ID: 30901717
[TBL] [Abstract][Full Text] [Related]
55. Targeting the EGFR signalling pathway in metastatic colorectal cancer.
Napolitano S; Martini G; Ciardiello D; Del Tufo S; Martinelli E; Troiani T; Ciardiello F
Lancet Gastroenterol Hepatol; 2024 Jul; 9(7):664-676. PubMed ID: 38697174
[TBL] [Abstract][Full Text] [Related]
56. Lipidome in colorectal cancer.
Yan G; Li L; Zhu B; Li Y
Oncotarget; 2016 May; 7(22):33429-39. PubMed ID: 26967051
[TBL] [Abstract][Full Text] [Related]
57. Novel and Emerging Targeted Therapies of Colorectal Cancer.
Finnberg N; Gokare P; El-Deiry WS
Curr Clin Pharmacol; 2015; 10(4):279-98. PubMed ID: 26548905
[TBL] [Abstract][Full Text] [Related]
58. Rationally designed treatment for metastatic colorectal cancer: current drug development strategies.
Spiliopoulou P; Arkenau HT
World J Gastroenterol; 2014 Aug; 20(30):10288-95. PubMed ID: 25132745
[TBL] [Abstract][Full Text] [Related]
59. Clinical, biological, and molecular aspects of metastasis in colorectal cancer.
Stein U; Schlag PM
Recent Results Cancer Res; 2007; 176():61-80. PubMed ID: 17607917
[TBL] [Abstract][Full Text] [Related]
60. Optimal management of metastatic colorectal cancer: current status.
McRee AJ; Goldberg RM
Drugs; 2011 May; 71(7):869-84. PubMed ID: 21568364
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
